SCHEDULE: Fortress Biotech Boosts Mustang Bio Stake to 8.0%

Fortress Biotech, Inc. has increased its beneficial ownership in Mustang Bio, Inc. to 8.0% following an annual equity grant and maintains a voting majority through preferred stock.

Summary

• Fortress Biotech, Inc. (Reporting Person) now beneficially owns 537,243 shares of Mustang Bio, Inc. (Issuer) common stock.
• This represents 8.0% of Mustang Bio's outstanding common stock.
• The increase is primarily due to an Annual Equity Grant of 278,385 shares of common stock received by Fortress Biotech under a Founders Agreement.
• Fortress Biotech holds 250,000 shares of Mustang Bio's Class A preferred stock, which are convertible into 333 shares of common stock and grant Fortress Biotech a voting majority.
• Holders of Class A preferred stock receive annual PIK Dividends on January 1, equal to 2.5% of Mustang Bio's fully-diluted outstanding capitalization in common stock.
• Fortress Biotech also holds 1,333 shares of Mustang Bio common stock underlying Warrants issued to its Chairman, President, CEO, Dr. Lindsay A. Rosenwald, and Executive Vice Chairman, Michael S. Weiss.

Sentiment

Score: 6

Explanation: The filing reflects a stable, ongoing strategic relationship and control structure between Fortress Biotech and Mustang Bio. The increase in ownership is routine and expected, indicating continued commitment from the major shareholder, which can be seen as positive for stability. However, the significant control and potential dilution from PIK dividends could be viewed less favorably by minority shareholders.

Positives

• Fortress Biotech, a biotechnology product developer, is increasing its stake in Mustang Bio, indicating continued strategic interest and commitment.
• Fortress Biotech maintains a voting majority in Mustang Bio through its Class A preferred stock, providing stable control and strategic alignment.
• The annual equity grant mechanism ensures ongoing alignment between Fortress Biotech and Mustang Bio's long-term growth.

Negatives

• The significant control exerted by Fortress Biotech through its Class A preferred stock and voting majority could limit the influence of other common stockholders.
• The PIK Dividend structure, paying in common stock, could lead to dilution for existing common shareholders over time.

Risks

• The Class A preferred stock held by Fortress Biotech grants it a voting majority, potentially limiting the influence of other common stockholders on corporate decisions.
• The annual PIK Dividend, paid in common stock, could result in dilution for other common shareholders.
• The Warrants held by Fortress Biotech's executives have a high exercise price ($110.25 per share), which may not be met if the stock price does not significantly appreciate.

Future Outlook

The filing indicates an ongoing relationship between Fortress Biotech and Mustang Bio, with Fortress Biotech continuing to receive annual equity grants and maintaining a controlling voting interest through its preferred stock. The Warrants held by executives suggest a long-term incentive structure tied to Mustang Bio's performance until 2035.

Management Comments

• Lindsay A. Rosenwald, M.D. / Chairman, President and Chief Executive Officer of Fortress Biotech, Inc. certified the information set forth in this statement as true, complete, and correct.

Industry Context

This filing highlights a common structure in the biotechnology sector where a founding or major investor (Fortress Biotech) maintains significant control and strategic influence over a spin-off or portfolio company (Mustang Bio) through a combination of common stock, preferred stock with enhanced voting rights, and ongoing equity grants. This model aims to align the interests of the parent company with the growth of its subsidiary, particularly in the capital-intensive and long-development-cycle biotech industry.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Fortress Biotech, Inc. is party to a Second Amended and Restated Founders Agreement with Mustang Bio, Inc., which governs the annual equity grants.
• Fortress Biotech, Inc. issued Warrants for Mustang Bio common stock to Lindsay A. Rosenwald, M.D. (Fortress's Chairman, President, CEO) and Michael S. Weiss (Fortress's Executive Vice Chairman, Strategic Development, and Mustang Bio's Executive Chairman).

Stakeholder Impact

• Shareholders (Common): Experience ongoing dilution from annual equity grants and PIK Dividends paid in common stock. Their voting power is significantly overshadowed by Fortress Biotech's preferred stock.
• Fortress Biotech (as a shareholder): Benefits from increased ownership, continued voting control, and annual equity grants/PIK Dividends, reinforcing its strategic position.
• Management (of both companies): Key executives of Fortress Biotech (who also serve on Mustang Bio's board) hold Warrants, aligning their personal incentives with Mustang Bio's long-term stock performance.

Next Steps

• Fortress Biotech will continue to receive annual equity grants from Mustang Bio on January 1 of each year.
• Fortress Biotech will continue to receive PIK Dividends on its Class A preferred stock on each January 1 until conversion or redemption.
• The Warrants held by Fortress Biotech executives are exercisable until July 15, 2035.

Key Dates

Recommendation

The filing primarily details an expected increase in beneficial ownership by Fortress Biotech in Mustang Bio due to pre-existing agreements, including an annual equity grant and PIK dividends. While Fortress Biotech maintains significant control and strategic alignment, which provides stability, the ongoing dilution from these grants and dividends for common shareholders is a factor. There are no new material operational or financial disclosures that would warrant a change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate, acknowledging the stable but controlled nature of the investment.

Keywords

Mustang Bio, Fortress Biotech, Schedule 13D/A, Beneficial Ownership, Equity Grant, Preferred Stock, Voting Control, Biotechnology, SEC Filing, Shareholder Update, Warrants, Corporate Governance